REPLIGEN CORP Payments of Merger Related Costs, Financing Activities
REPLIGEN CORP (RGEN) reported Payments of Merger Related Costs, Financing Activities of $1.72 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities · last filed 2019-03-01
- REPLIGEN CORP payments of merger related costs, financing activities for the quarter ending 2017-12-31 was $13.00K, a 95.67% decline year-over-year.
- REPLIGEN CORP payments of merger related costs, financing activities for the quarter ending 2017-09-30 was $25.00K.
- REPLIGEN CORP payments of merger related costs, financing activities for the quarter ending 2017-06-30 was $14.00K.
- REPLIGEN CORP payments of merger related costs, financing activities for the quarter ending 2017-03-31 was $1.66M, a 233.94% increase year-over-year.
- REPLIGEN CORP payments of merger related costs, financing activities for fiscal 2017 was $1.72M, a 114.91% increase from fiscal 2016.
- REPLIGEN CORP payments of merger related costs, financing activities for fiscal 2016 was $798.00K, a 706.06% increase from fiscal 2015.
- REPLIGEN CORP payments of merger related costs, financing activities for fiscal 2015 was $99.00K.
| Period end | Payments of Merger Related Costs, Financing Activities 3 month | Payments of Merger Related Costs, Financing Activities 6 month | Payments of Merger Related Costs, Financing Activities 9 month | Payments of Merger Related Costs, Financing Activities 9 month as first filed | Payments of Merger Related Costs, Financing Activities 12 month |
|---|---|---|---|---|---|
| 2017-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $38.00K derived: sum of 2 quarters · filed 2019-03-01 | $52.00K derived: sum of 3 quarters · filed 2019-03-01 | $1.72M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $25.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $39.00K derived: sum of 2 quarters · filed 2018-11-01 | $1.70M 10-Q · filed 2018-11-01 | $2.00M derived: sum of 4 quarters · filed 2019-03-01 | |
| 2017-06-30 | $14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $1.68M 10-Q · filed 2018-08-02 | $1.98M derived: sum of 3 quarters · filed 2019-03-01 | $1.98M derived: sum of 4 quarters · filed 2019-03-01 | |
| 2017-03-31 | $1.66M 10-Q · filed 2018-05-08 | $1.96M derived: sum of 2 quarters · filed 2019-03-01 | $1.96M derived: sum of 3 quarters · filed 2019-03-01 | $1.96M derived: sum of 4 quarters · filed 2019-03-01 | |
| 2016-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $300.00K derived: sum of 2 quarters · filed 2019-03-01 | $300.00K derived: sum of 3 quarters · filed 2019-03-01 | $798.00K 10-K · filed 2019-03-01 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $0.00 derived: sum of 2 quarters · filed 2017-11-09 | $498.00K 10-Q · filed 2017-11-09 | $498.00K derived: sum of 4 quarters · filed 2018-02-22 | |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $498.00K 10-Q · filed 2017-08-03 | $498.00K derived: sum of 3 quarters · filed 2018-02-22 | $498.00K derived: sum of 4 quarters · filed 2018-02-22 | |
| 2016-03-31 | $498.00K 10-Q · filed 2017-05-04 | $498.00K derived: sum of 2 quarters · filed 2018-02-22 | $498.00K derived: sum of 3 quarters · filed 2018-02-22 | $498.00K derived: sum of 4 quarters · filed 2018-02-22 | |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $0.00 derived: sum of 2 quarters · filed 2018-02-22 | $0.00 derived: sum of 3 quarters · filed 2018-02-22 | $99.00K 10-K · filed 2018-02-22 | |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $0.00 derived: sum of 2 quarters · filed 2016-11-03 | $99.00K 10-Q · filed 2016-11-03 | ||
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $99.00K 10-Q · filed 2016-08-04 | |||
| 2015-03-31 | $99.00K 10-Q · filed 2016-05-05 | ||||
| 2014-09-30 | $604.00K 10-Q · filed 2015-11-05 | $603.68K 10-Q · filed 2014-11-07 | |||
| 2013-09-30 | $376.12K 10-Q · filed 2014-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |